Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

According to the American Porphyria Foundation (APF), EPP and XLP combined are the third most common porphyria, with an incidence of possibly two to five per million people, and are the most ...